Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 4, 2007, Pages 885-888

  Poveda, Eva ^a   De Mendoza, Carmen ^a   Martin Carbonero, Luz ^a   Corral, Angélica ^a   Briz, Verónica ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Genetic barrier; New antiretrovirals; Salvage therapies

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; INDINAVIR; LEUCINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHIONINE; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; TIPRANAVIR; VALINE;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MEDICAL DECISION MAKING; MULTIVARIATE ANALYSIS; NONHUMAN; PATIENT REFERRAL; PREVALENCE; SCORING SYSTEM; SEQUENCE ANALYSIS; SPAIN; TREATMENT FAILURE;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; SPAIN; SULFONAMIDES;

EID: 34548749164     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm276     Document Type: Article

References (10)

1. Palella F, Delany K, Moorman A et al. HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1998; 338: 853-60.
2. De Mendoza C, Valer L, Ribera E et al. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. HIV Clin Trials 2006; 7:163-71.
3. Lefebvre E, De Meyer S, De Paepe E et al. Darunavir TMC114)/r provides greater efficacy benefits versus control protease inhibitor(s), regardless of the protease inhibitor or sensitivity to the protease inhibitor: POWER 1 and 2 trials. In: Abstracts of the Eighth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2006. Abstract P29.
4. Johnson V, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Topics HIV Med 2006; 14: 125-30.
5. Cohen C, Falcon R, Rinehart A et al. Factors influencing darunavir/r efficacy in treatment-experienced HIV patients: POWER 1, 2, and 3 pooled 48-week analysis. In: Abstracts of the Forty-fourth IDSA, Toronto, Canada, 2006. Abstract P688.
6. King N, Prabu-Jeyabalan M, Nalivaika E et al. Structural and thermodynamic basis for the binding of TMC114, a next-goneration HIV type 1 protease inhibitor. J Virol 2004;78:12012-21.
7. Arvieux C, Tribut O. Amprenavir or fosamprenavir plus ritonavir in HIV infection: Pharmacology, offic and tolerability profile. Drugs 2005;65:633-59.
8. De Meyer S, Azijn H, Franse E et al. The pathway leading to TMC114 resistance is different for TMC114 compared with other protease inhibitors. In: Abstracts of the Fifteenth International HIV Drug Resistance Workshop Sitges Spain, 2006. Abstract 73.
9. Hou T, Yu R. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexes with amprenavir and two amprenavir-related inhibitors: Mechanism for binding and drug resistance. J Med Chem 2007; 50: 1177-88.
10. Picchio G, Vangeneugden T, Van Baelen B et al. Prior utilization or resistance to amprenavir at screening has minimal effect on the 48-week response to darunavir/r in the POWER 1, 2, and 3 studies. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA, 2007. Abstract 609. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.